82 related articles for article (PubMed ID: 8647649)
1. Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents.
Damia G; Imperatori L; Stefanini M; D'Incalci M
Int J Cancer; 1996 Jun; 66(6):779-83. PubMed ID: 8647649
[TBL] [Abstract][Full Text] [Related]
2. The XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-136.
Clingen PH; De Silva IU; McHugh PJ; Ghadessy FJ; Tilby MJ; Thurston DE; Hartley JA
Nucleic Acids Res; 2005; 33(10):3283-91. PubMed ID: 15944449
[TBL] [Abstract][Full Text] [Related]
3. Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin.
De Silva IU; McHugh PJ; Clingen PH; Hartley JA
Nucleic Acids Res; 2002 Sep; 30(17):3848-56. PubMed ID: 12202770
[TBL] [Abstract][Full Text] [Related]
4. A method to monitor replication fork progression in mammalian cells: nucleotide excision repair enhances and homologous recombination delays elongation along damaged DNA.
Johansson F; Lagerqvist A; Erixon K; Jenssen D
Nucleic Acids Res; 2004 Nov; 32(20):e157. PubMed ID: 15537835
[TBL] [Abstract][Full Text] [Related]
5. Nucleotide excision repair in the third kingdom.
Ogrünç M; Becker DF; Ragsdale SW; Sancar A
J Bacteriol; 1998 Nov; 180(21):5796-8. PubMed ID: 9791138
[TBL] [Abstract][Full Text] [Related]
6. Different Patterns of Platinum Resistance in Ovarian Cancer Cells with Homologous Recombination Proficient and Deficient Background.
Chiappa M; Guffanti F; Grasselli C; Panini N; Corbelli A; Fiordaliso F; Damia G
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474294
[TBL] [Abstract][Full Text] [Related]
7. ERCC1 abundance is an indicator of DNA repair-apoptosis decision upon DNA damage.
Erdemir Sayan S; Sreekumar R; Bhome R; Mirnezami A; Yagci T; Sayan AE
Cell Death Discov; 2024 Jan; 10(1):47. PubMed ID: 38272916
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin in Ovarian Cancer Treatment-Known Limitations in Therapy Force New Solutions.
Zoń A; Bednarek I
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108749
[TBL] [Abstract][Full Text] [Related]
9. Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer.
Sassu CM; Palaia I; Boccia SM; Caruso G; Perniola G; Tomao F; Di Donato V; Musella A; Muzii L
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948446
[TBL] [Abstract][Full Text] [Related]
10. Predictive modeling of gene expression regulation.
Regondi C; Fratelli M; Damia G; Guffanti F; Ganzinelli M; Matteucci M; Masseroli M
BMC Bioinformatics; 2021 Nov; 22(1):571. PubMed ID: 34837938
[TBL] [Abstract][Full Text] [Related]
11. Targeting DNA Damage Response and Repair to Enhance Therapeutic Index in Cisplatin-Based Cancer Treatment.
Kiss RC; Xia F; Acklin S
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360968
[TBL] [Abstract][Full Text] [Related]
12. The ZEB2-dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in colorectal cancer.
Sreekumar R; Al-Saihati H; Emaduddin M; Moutasim K; Mellone M; Patel A; Kilic S; Cetin M; Erdemir S; Navio MS; Lopez MA; Curtis N; Yagci T; Primrose JN; Price BD; Berx G; Thomas GJ; Tulchinsky E; Mirnezami A; Sayan AE
Mol Oncol; 2021 Aug; 15(8):2065-2083. PubMed ID: 33931939
[TBL] [Abstract][Full Text] [Related]
13. Impact of ERCC1, XPF and DNA Polymerase β Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts.
Guffanti F; Alvisi MF; Caiola E; Ricci F; De Maglie M; Soldati S; Ganzinelli M; Decio A; Giavazzi R; Rulli E; Damia G
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32847049
[TBL] [Abstract][Full Text] [Related]
14. XPF-ERCC1: Linchpin of DNA crosslink repair.
McHugh PJ
PLoS Genet; 2020 Apr; 16(4):e1008616. PubMed ID: 32271747
[No Abstract] [Full Text] [Related]
15. Platinum Resistance in Ovarian Cancer: Role of DNA Repair.
Damia G; Broggini M
Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30669514
[TBL] [Abstract][Full Text] [Related]
16. Functional Comparison of XPF Missense Mutations Associated to Multiple DNA Repair Disorders.
Marín M; Ramírez MJ; Carmona MA; Jia N; Ogi T; Bogliolo M; Surrallés J
Genes (Basel); 2019 Jan; 10(1):. PubMed ID: 30658521
[TBL] [Abstract][Full Text] [Related]
17.
Vencioneck Dutra JC; Moisés Ferreira J; Costalonga Pereira PR; Ben-Hur de Oliveira J; Vitorino Gervásio S; Bernardes Xavier M; Mantovanelli da Mota M; Luz ACD; Rodrigues Pretti I; Seibert França H; Masrouah Jamal C; Pimentel Batitucci MDC
Pharmaceuticals (Basel); 2018 Nov; 11(4):. PubMed ID: 30477180
[No Abstract] [Full Text] [Related]
18. Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts.
Guffanti F; Fratelli M; Ganzinelli M; Bolis M; Ricci F; Bizzaro F; Chilà R; Sina FP; Fruscio R; Lupia M; Cavallaro U; Cappelletti MR; Generali D; Giavazzi R; Damia G
Oncotarget; 2018 May; 9(37):24707-24717. PubMed ID: 29872499
[TBL] [Abstract][Full Text] [Related]
19. BERing the burden of damage: Pathway crosstalk and posttranslational modification of base excision repair proteins regulate DNA damage management.
Limpose KL; Corbett AH; Doetsch PW
DNA Repair (Amst); 2017 Aug; 56():51-64. PubMed ID: 28629773
[TBL] [Abstract][Full Text] [Related]
20. The 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs.
Rulli E; Guffanti F; Caiola E; Ganzinelli M; Damia G; Garassino MC; Piva S; Ceppi L; Broggini M; Marabese M
Sci Rep; 2016 Dec; 6():39217. PubMed ID: 27966655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
